Showing results (1-10 of 25) with videos related to
Sort By:
Pageof 3
Pharmacotherapy|September 20, 2011
Pharmacogenomics in the assessment of therapeutic risks versus benefits: inside the United States Food and Drug AdministrationIssam Zineh, Michael A PacanowskiPharmacotherapy|June 13, 2017
Clinical Trial Designs to Support Clinical Utility of Pharmacogenomic TestingKatarzyna Drozda, Michael A PacanowskiThe Annals of Pharmacotherapy|September 15, 2005
Interferon gamma-1b in the treatment of idiopathic pulmonary fibrosisMichael A Pacanowski, Guy W AmsdenJACC. Basic to Translational Science|September 4, 2018
Pharmacogenetic Labeling of FDA-Approved Drugs: A Regulatory RetrospectiveKatarzyna Drozda, Michael A Pacanowski, Christian Grimstein, et al.Expert Opinion on Drug Metabolism & Toxicology|May 20, 2008
Interindividual variability in oral antidiabetic drug disposition and response: the role of drug transporter polymorphismsMichael A Pacanowski, Charles W Hopley, Christina L AquilanteJournal of the American College of Cardiology|January 31, 2009
Cardiovascular therapies and associated glucose homeostasis: implications across the dysglycemia continuumRhonda M Cooper-DeHoff, Michael A Pacanowski, Carl J PepinePharmacogenomics|January 19, 2013
Consistency of drug-drug and gene-drug interaction information in US FDA-approved drug labelsDaniela J Conrado, Hobart L Rogers, Issam Zineh, et al.Journal of Clinical Lipidology|August 4, 2009
Plasma Coenzyme Q10 Predicts Lipid-lowering Response to High-Dose AtorvastatinMichael A Pacanowski, Reginald F Frye, Osatohanmen Enogieru, et al.Therapeutic Delivery|July 27, 2012
Biomarkers to improve the benefit/risk balance for approved therapeutics: a US FDA perspective on personalized medicineKim E Sapsford, Zivana Tezak, Marina Kondratovich, et al.Pharmacogenetics and Genomics|April 9, 2016
Dosing recommendations for pharmacogenetic interactions related to drug metabolismKelly K Filipski, Michael A Pacanowski, Anuradha Ramamoorthy, et al.Pageof 3